| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/31/2002 | WO2002007702A2 Liposomic formulation of clobetasol propionate |
| 01/31/2002 | WO2002007683A1 Antimicotic nail varnish composition |
| 01/31/2002 | WO2002007674A2 Enhancing compound penetration into hair follicles |
| 01/31/2002 | WO2002007672A2 A medicinal aerosol formulation |
| 01/31/2002 | WO2002007520A2 Antimicrobial composition useful for the treatment of bovine mastitis |
| 01/31/2002 | WO2001072280A3 Microspheres for gene therapy |
| 01/31/2002 | WO2001070270A3 Base compositions for preparing surfactant free topical compositions |
| 01/31/2002 | WO2001070172A3 Solid, water-dispersible, oral pharmaceutical form comprising rifampicin, isoniazid and pyridoxine hydrochloride, method for obtaining and presenting said pharmaceutical form |
| 01/31/2002 | WO2001064185A3 Method for making, loading and sealing a cell or drug encapsulation device, and such a device |
| 01/31/2002 | WO2001064182A3 Improvements in or relating to the delivery of oral drugs |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001058492A3 Carrier particles for drug delivery and process for preparation |
| 01/31/2002 | WO2001058425A3 Pharmaceutical composition for pulmonary delivery |
| 01/31/2002 | WO2001056546A3 Magnetoliposome composition for targeted treatment of biological tissue |
| 01/31/2002 | WO2001052894A3 Nasally administrable cyclic peptide compositions |
| 01/31/2002 | WO2001049272A3 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| 01/31/2002 | WO2001049270B1 Odor-masking coating for a pharmaceutical preparation |
| 01/31/2002 | WO2001041736A3 Microchip devices for delivery of molecules and methods of fabrication thereof |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2001022791A3 Controlled release compositions comprising nimesulide |
| 01/31/2002 | WO2001017580A3 Fluid delivery device with temperature controlled energy source |
| 01/31/2002 | WO2000072827A9 Porous drug matrices and methods of manufacture thereof |
| 01/31/2002 | WO2000025568A9 Gellan gum seed coating |
| 01/31/2002 | US20020013557 Implantable vascular access device |
| 01/31/2002 | US20020013545 Synthetic muscle based diaphragm pump apparatuses |
| 01/31/2002 | US20020013497 Alkylation, blocking |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013353 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 01/31/2002 | US20020013340 Treatment of ocular disease |
| 01/31/2002 | US20020013338 Incorporating stabilizing effective amount of a hydrochloric acid donor to pharmaceutical formulation containing an active component subject to degradation |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013305 Aqueous solvent for corticosteroids |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013301 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency |
| 01/31/2002 | US20020013298 Such as multiple sclerosis, by administering antimicrotubule agent: epothilones, discodermolide, deuterium oxide, hexylene glycol, tubercidin, LY-290181, alumimum fluoride, glycine ethyl ester, or ethylene glycol bis(succinimidylsuccinate) |
| 01/31/2002 | US20020013275 Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity |
| 01/31/2002 | US20020013273 Method for producing sustained-release formulations |
| 01/31/2002 | US20020013272 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions |
| 01/31/2002 | US20020013271 Improved bioavailability and safety in compact dosage form using particles stabilized with a combination of phospholipid and at least one nonionic, anionic or cationic surfactant adhered to the drug core surface; nonagglomerants |
| 01/31/2002 | US20020013252 Particulate composite material for the controlled release of an active ingredient |
| 01/31/2002 | US20020013088 Coaxial connector having detachable locking sleeve |
| 01/31/2002 | US20020012998 Gene transfer composition; for use in the transfection of mammalian cells |
| 01/31/2002 | US20020012957 Plasma-like solution |
| 01/31/2002 | US20020012723 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012706 Method of making granular pharmaceutical vehicle |
| 01/31/2002 | US20020012705 Polymer constructs |
| 01/31/2002 | US20020012704 Water-insoluble drug particle process |
| 01/31/2002 | US20020012703 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 01/31/2002 | US20020012702 Controlled release anti-inflammatory oral formulation and a process for the preparation thereof |
| 01/31/2002 | US20020012701 Mixture of polyvinyl acetate, polyvinylpyrrolidone, active ingredients, water-soluble polymers or low or high molecular weight lipophilic additives are heated, granulated |
| 01/31/2002 | US20020012700 Portion of pseudoephedrine is contained in core whereby release into environment of use is sustained, cetirizine is contained as immediate-release component; antiallergens, spasmolytics |
| 01/31/2002 | US20020012699 Providing membrane protein in solution, providing solution of preformed liposomes formed by combining mixture of phospholipids with solution of unsaturated fatty acid, incubating |
| 01/31/2002 | US20020012698 Magnetosomes, method for making and using |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012695 Increased skin permeation of drug, and allows improved drug stability within the adhesive layer |
| 01/31/2002 | US20020012694 For delivery of 7 alpha -methyl-19-nortestosterone (MENT) |
| 01/31/2002 | US20020012691 Time-release agents, therapy in humans, veterinary medicine |
| 01/31/2002 | US20020012688 Powdery composition for nasal administration |
| 01/31/2002 | US20020012687 Solid dose delivery vehicle and methods of making same |
| 01/31/2002 | US20020012685 Providing flexible strip of material, applying a layer of a tooth whitening substance selected from peroxides, metal chlorites, perborates, percarbonates, peroxyacids, hypochlorites to front surface of teeth, conforming strip |
| 01/31/2002 | US20020012684 10-hydroxy-2-decenoic acid compounds for promoting desquamation/epidermal renewal of the skin and/or combating skin aging |
| 01/31/2002 | US20020012680 Compositions and methods for improved delivery of lipid regulating agents |
| 01/31/2002 | US20020012679 Process for manufacturing coated gabapentin or pregabalin particles |
| 01/31/2002 | US20020012677 Pharmaceutical composition for treating dysmenorrhea and premature labor |
| 01/31/2002 | US20020012676 For inhibiting gastric acid secretion in mammals and man |
| 01/31/2002 | US20020012675 Time-release agent containing poorly soluble agent such as a drug |
| 01/31/2002 | US20020012674 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 01/31/2002 | US20020012673 Immunstimulating lipid formulation |
| 01/31/2002 | US20020012652 Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| 01/31/2002 | US20020012651 Release of therapeutic agents in a vessel or tissue |
| 01/31/2002 | US20020012649 Lipid composition containing a liquid crystal structure |
| 01/31/2002 | US20020012648 Cosmetics, emulsion stability, storage stability, skin feel |
| 01/31/2002 | US20020012633 Sildenafil citrate chewing gum formulations and methods of using the same |
| 01/31/2002 | US20020011186 Flaky fine powder, production thereof, and cosmetic |
| 01/31/2002 | US20020010982 Dispersion of the solution or suspension and the second vehicle and extraction of the vehicles occur simultaneously immediately on introduction of the fluids into the vessel, by the action of the supercritical fluid |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10033855A1 Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability |
| 01/31/2002 | DE10033853A1 Transdermal therapeutic system, containing highly dispersed silicon dioxide in matrix or adhesive layer to promote drug permeation through the skin |
| 01/31/2002 | DE10033023A1 Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen Film coating composition based on cellulose derivatives and sugar alcohols |
| 01/31/2002 | DE10032537A1 Dermales System, enthaltend 2-(3-Benzophenyl)Propionsäure A dermal system, comprising 2- (3-benzophenyl) propionic acid |
| 01/31/2002 | DE10032456A1 Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen Rapidly disintegrating dosage form for the delivery of drugs to the oral cavity or into body cavities |
| 01/31/2002 | CA2417108A1 A method for treating celiac disease |
| 01/31/2002 | CA2416257A1 Compositions and films for capsule manufacture |
| 01/31/2002 | CA2415345A1 Linkage of agents using microparticles |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2412544A1 Polypeptide delivery ii-2 |
| 01/31/2002 | CA2412392A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | CA2412376A1 Pharmaceutical suspension compositions lacking a polymeric suspending agent |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/30/2002 | EP1175913A1 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof |
| 01/30/2002 | EP1175912A1 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| 01/30/2002 | EP1175908A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 01/30/2002 | EP1175899A1 Starch and lactose granulate |
| 01/30/2002 | EP1175477A1 Cleaning compositions and tablets |
| 01/30/2002 | EP1175430A1 Antisense-oligos with better stability and antisense effect |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |